Advertisement

Journal of Neuro-Oncology

, Volume 137, Issue 3, pp 463–468 | Cite as

MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS

  • Alexander Baraniskin
  • Monika Chomiak
  • Guido Ahle
  • Thomas Gress
  • Malte Buchholz
  • Michael Turewicz
  • Martin Eisenacher
  • Michelle Margold
  • Uwe Schlegel
  • Wolff Schmiegel
  • Stephan Hahn
  • Roland Schroers
Laboratory Investigation

Abstract

Primary lymphomas of the central nervous system (PCNSL) are highly aggressive tumors affecting exclusively the CNS, meninges, and eyes. PCNSL must be separated from secondary spread of systemic lymphoma to the CNS (SCNSL), which may occur at diagnosis or relapse of systemic lymphomas. At present, there are no valid methods to distinguish PCNSL from SCNSL based on tumor biopsy because of similar histological presentation. However, SCNSL and PCNSL are different in terms of prognosis and adequate therapy protocols. MicroRNA expression profiles of CSF samples collected from SCNSL and PCNSL patients were compared using microRNA arrays. MiR-30c revealed the largest differential expression and was selected for validation by RT-PCR on 61 CSF samples from patients with PCNSL and 14 samples from SCNSL. MiR-30c was significantly increased in patients with SCNSL compared to PCNSL (p < 0.001). MiR-30c levels in CSF enabled the differentiation of patients with PCNSL from SCNSL with an area under the curve (AUC) of 0.86, with a sensitivity of 90.9% and a specificity of 85.5%. Our data suggest that miR-30c detected in the CSF can serve as biomarker for distinction between PCNSL and SCNSL. The validation in a larger cohort is needed. With respect to its function, miR-30c may facilitate lymphoma cells to engraft into CNS by interaction with CELSR3 gene that controls the function of ependymal cilia and, thus, affects the circulation of CSF.

Keywords

Primary central nervous system lymphoma Secondary central nervous system lymphoma Cerebrospinal fluid (CSF) MicroRNA (miRNA) qRT-PCR MiR-30c 

Notes

Acknowledgements

The authors thank Andrea Reinert for the excellent technical assistance.

Author contributions

MC, AB, TG, MB performed the experiments. GA, JK, MM, US collected clinical samples. MT and ME. analyzed the results statistically, AB, MC, SH, US, WS and RS designed the research. AB, RS analyzed the results and wrote the paper.

Funding

This study was supported by the a Grant from the Ruhr-University of Bochum (FORUM), and by a Grant (PURE) from the Ministry of Science, North Rhine-Westphalia, Germany and by de.NBI, a project of the German Federal Ministry of Education and Research (BMBF).

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interest.

Supplementary material

11060_2018_2749_MOESM1_ESM.docx (46 kb)
Supplementary material 1 (DOCX 46 KB)
11060_2018_2749_MOESM2_ESM.docx (52 kb)
Supplementary material 2 (DOCX 51 KB)
11060_2018_2749_MOESM3_ESM.docx (505 kb)
Supplementary material 3 (DOCX 505 KB)
11060_2018_2749_MOESM4_ESM.docx (19 kb)
Supplementary material 4 (DOCX 19 KB)
11060_2018_2749_MOESM5_ESM.docx (19 kb)
Supplementary material 5 (DOCX 18 KB)
11060_2018_2749_MOESM6_ESM.docx (21 kb)
Supplementary material 6 (DOCX 21 KB)

References

  1. 1.
    Ney DE, Deangelis LM (2010) Management of central nervous system lymphoma. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla Favera R (eds) Non-Hodgkin lymphomas. Lippincott Willilams & Wilkins, Philadelphia, pp 527–539Google Scholar
  2. 2.
    Shenkier TN, Blay JY, O’Neill BP et al (2005) Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23:2233–2239CrossRefPubMedGoogle Scholar
  3. 3.
    Deckert M, Paulus W, Kluin PM et al (2016) Lymphomas. In: World Health Organization histological classification of tumours of the central nervous system, 4th revised edn. pp 271–283Google Scholar
  4. 4.
    Ferreri AJ, Assanelli A, Crocchiolo R et al (2009) Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol 27:61–70CrossRefPubMedGoogle Scholar
  5. 5.
    Schmitz N, Zeynalova S, Glass B et al (2012) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23(5):1267–1273CrossRefPubMedGoogle Scholar
  6. 6.
    Doolittle ND, Abrey LE, Shenkier TN et al (2008) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an international primary CNS lymphoma collaborative group report. Blood 111(3):1085–1093CrossRefPubMedGoogle Scholar
  7. 7.
    Akkas BE, Vural GU (2013) The incidence of secondary central nervous system involvement in patients with non-Hodgkin’s lymphoma as detected by 18F-FDG PET/CT. Nucl Med Commun 34(1):50–56CrossRefPubMedGoogle Scholar
  8. 8.
    Korfel A, Schlegel U (2013) Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9(6):317–327CrossRefPubMedGoogle Scholar
  9. 9.
    Korfel A, Chamberlain M, Neuwelt E et al (2016) Therapy for secondary CNS involvement in malignant lymphomas: no standard yet! J Clin Oncol 34(15):1829–1830CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117(11):3140–3146CrossRefPubMedGoogle Scholar
  11. 11.
    Baraniskin A, Kuhnhenn J, Schlegel U et al (2012) MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurooncol 109(2):239–244CrossRefPubMedGoogle Scholar
  12. 12.
    Marabita F, de Candia P, Torri A et al (2016) Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 17(2):204–212CrossRefPubMedGoogle Scholar
  13. 13.
    Cogswell JP, Ward J, Taylor IA et al (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14(1):27–41CrossRefPubMedGoogle Scholar
  14. 14.
    Baraniskin A, Kuhnhenn J, Schlegel U et al (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 14(1):29–33CrossRefPubMedGoogle Scholar
  15. 15.
    Fischer L, Hummel M, Korfel A et al (2011) Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13(10):1090–1098CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A et al (2012) MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33(4):732–739CrossRefPubMedGoogle Scholar
  17. 17.
    Chang TC, Yu D, Lee YS et al (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40:43–50CrossRefPubMedGoogle Scholar
  18. 18.
    Kong X, Xu X, Yan Y et al (2014) Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS ONE 9:e90810CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Rodriguez-Gonzalez FG, Sieuwerts AM et al (2011) MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 127:43–51CrossRefPubMedGoogle Scholar
  20. 20.
    Wu F, Zhu S, Ding Y et al (2009) MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 15:1550–1557CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Budhu A, Jia HL, Forgues M et al (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47(3):897–907CrossRefPubMedGoogle Scholar
  22. 22.
    Wang XJ, Zhang DL, Xu ZG et al (2014 Dec) Understanding cadherin EGF LAG seven-pass G-type receptors. J Neurochem 131(6):699–711CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tissir F, Qu Y, Montcouquiol M, Zhou L et al (2010) Lack of cadherins Celsr2 and Celsr3 impairs ependymal ciliogenesis, leading to fatal hydrocephalus. Nat Neurosci 13(6):700–707CrossRefPubMedGoogle Scholar
  24. 24.
    Fletcher CD, Kahl B (2014) Central nervous system involvement in diffuse large B-cell lymphoma: An analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 55:2228–2240CrossRefPubMedGoogle Scholar
  25. 25.
    Schmitz N, Zeynalova S, Nickelsen M et al (2016) CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34(26):3150–3156CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineRuhr-University of Bochum, Knappschaftskrankenhaus Bochum-LangendreerBochumGermany
  2. 2.Department of NeurologyHôpitaux Civils de ColmarColmarFrance
  3. 3.Department of GastroenterologyUniversity HospitalMarburgGermany
  4. 4.Unit of Medical Bioinformatics, Medizinisches Proteom-CenterRuhr-University BochumBochumGermany
  5. 5.Department of NeurologyKnappschaftskrankenhaus, Ruhr-University of BochumBochumGermany
  6. 6.Department of Molecular GI-Oncology, Center of Clinical ResearchRuhr-University of BochumBochumGermany

Personalised recommendations